ALX Oncology Holdings Inc. - Common Stock — balance (NASDAQ:ALXO) | MetaTrader

Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas

Activos totales 436.05 M380.18 M306.49 M242.55 M147.78 M59.05 M Total de pasivos 6.21 M17.13 M43.02 M52.84 M34.16 M33.06 M Capital total 429.85 M363.05 M263.46 M189.71 M113.62 M25.98 M Total de pasivos y patrimonio neto 436.05 M380.18 M306.49 M242.55 M147.78 M59.05 M Deuda total 5.42 M—9.39 M9.64 M9.47 M10.71 M Deuda neta 5.42 M—9.39 M9.64 M9.47 M-40.26 M

Noticias

Informe de resultados de ALX Oncology: supera las previsiones del primer trimestre de 2026

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ALXO) 2026-05-08

Resultados de ALX Oncology Q1 2026: respuesta del 100% valida estrategia CD47

ALX Oncology presenta datos de ensayo en cáncer de mama con biomarcador CD47

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?

ALX Oncology nombra a Jeff Knight director de desarrollo

Wells Fargo inicia cobertura de ALX Oncology con calificación sobreponderada

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

IBRX Stock Jumps on Progress in NK Cell Therapy Production